Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma Plc LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.70 0.75% 94.20 455,313 16:35:16
Bid Price Offer Price High Price Low Price Open Price
94.60 94.80 95.20 93.40 94.10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 129.80 13.02 1.54 61.2 502
Last Trade Time Trade Type Trade Size Trade Price Currency
17:52:49 O 20,403 93.85 GBX

Alliance Pharma (APH) Latest News (1)

More Alliance Pharma News
Alliance Pharma Investors    Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
29/3/202109:15Alliance Pharma pays Dividends1,705
21/8/201817:36A Canadian Stock Worth Watching1
07/11/201615:35Alliance Pharma plc1
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-16 16:55:2693.8520,40319,148.22O
2021-04-16 16:55:0594.0519,34418,192.26O
2021-04-16 16:55:0393.812,6902,523.46O
2021-04-16 15:35:1694.20115,194108,512.75UT
2021-04-16 15:29:5394.802,0901,981.32AT
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

Alliance Pharma Daily Update: Alliance Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 93.50p.
Alliance Pharma Plc has a 4 week average price of 83.50p and a 12 week average price of 81.50p.
The 1 year high share price is 95.80p while the 1 year low share price is currently 68.20p.
There are currently 532,605,533 shares in issue and the average daily traded volume is 3,130,720 shares. The market capitalisation of Alliance Pharma Plc is £501,714,412.09.
2vdm: Looking fwd to hearing the webcast this pm (details below). Today's RNS - Results for the year ended 31 December 2020 OVERVIEW -- Strong performance from Consumer Healthcare brands, which now account for over two thirds of Group see-through revenues* o Kelo-cote(TM) revenues up 12% o Nizoral(TM) see-through revenues* up 4% o See-through revenues* overall up 1% to GBP93.0m (2019: GBP92.4m) o Statutory revenues up 2% to GBP85.3m (2019: GBP83.7m) -- Prescription Medicine revenues down 14% to GBP44.5m (2019: GBP51.9m), reflecting delays in routine treatments as a result of COVID-19 -- Group see-through revenue* in total down 5% (down 5% CCY*) to GBP137.5m (2019: GBP144.3m) -- Group statutory revenues down 4%, to GBP129.8m (2019: GBP135.6m) -- Substantial US acquisition completed in December 2020, bringing a highly successful and fast-growing brand, Amberen (TM), into the Group, and creating scale in the Group's US operations -- Underlying profit before tax up 2% to GBP33.5m (2019: GBP32.9m) -- Reported profit before tax down 58% to GBP13.0m (2019: GBP31.1m), due to non-cash impairment and amortisation charges, and acquisition costs relating to the Biogix Inc acquisition -- Group leverage post acquisition of Biogix Inc at 2.43 times, up from 1.48 times at December 2019; leverage expected to decrease to below 2.0 times during 2021 -- Free cash flow very strong at GBP34.1m, helped by favourable movements in net working capital -- Cash generated from operations up 19% to GBP46.4m (2019: GBP39.0m) -- Proposed final dividend payment of 1.074p per share, giving a total dividend of 1.610p (2019: 0.536p) FINANCIAL SUMMARY Year ended 31 December 2020 2019 Growth GBPm GBPm Revenue (see-through basis)* 137.5 144.3 -5% --------------------------------- ------- ------- ------- Revenue (statutory basis) 129.8 135.6 -4% --------------------------------- ------- ------- ------- Gross profit 82.8 86.1 -4% --------------------------------- ------- ------- ------- Underlying profit before taxation 33.5 32.9 2% --------------------------------- ------- ------- ------- Reported profit before taxation 13.0 31.1 -58% --------------------------------- ------- ------- ------- Underlying basic earnings per share 5.21p 5.09p 2% --------------------------------- ------- ------- ------- Reported basic earnings per share 1.54p 4.80p -68% --------------------------------- ------- ------- ------- Free cash flow* 34.1 29.1 17% --------------------------------- ------- ------- ------- Cash generated from operations 46.4 39.0 19% --------------------------------- ------- ------- ------- Leverage 2.43x 1.48x --------------------------------- ------- ------- ------- Net debt* 109.4 59.2 --------------------------------- ------- ------- ------- Proposed total dividend per share 1.610p 0.536p 200% --------------------------------- ------- ------- ------- * The performance of the Group is assessed using Alternative Performance Measures ("APMs"), which are measures that are not defined under IFRS, but are used by management to monitor ongoing business performance against both shorter term budgets and forecasts and against the Groups longer term strategic plans. APMs are defined in note 20. Specifically, see-through revenue includes sales from Nizoral(TM) as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in each of the Asia-Pacific territories transfer from J&J to Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15. Commenting on the results, Peter Butterfield, Alliance Pharma's Chief Executive Officer, said : "The Group delivered a robust operational and financial performance in 2020, despite the challenges of the pandemic. Whilst top line revenue growth was constrained, our Consumer Healthcare business has performed well and we have seen some strong performances from a number of our brands, in particular Kelo-cote. "Through maintaining good control of our operating costs, we have continued to deliver a resilient underlying operating performance and o ur free cash flow has also remained very strong, enabling us to pay down more of our debt than expected ahead of completing the Biogix acquisition in December 2020. "This strategically significant acquisition bears testament to our ability to continue to deliver on our longer-term growth strategy, notwithstanding the global pandemic. In addition to bringing another sizeable and fast-growing brand into the Group, it significantly enhances the scale of our business operations in the US, the world's largest consumer healthcare market, and in consumer healthcare more generally. "2021 has started well and we remain confident in our ability to continue to deliver a strong operational and financial performance, in line with market expectations. We look forward to regaining the strong momentum and revenue growth that the Group has enjoyed in recent years, whilst also benefiting from the additional scale and future growth opportunities that Amberen brings. "Whilst our near-term focus will be on integrating Biogix into our existing US business, we will continue to look for opportunities to selectively add to our portfolio in line with our strategy of acquiring consumer healthcare brands in international markets in which we already have a presence." CONFERENCE CALL & WEBCAST A conference call for analysts will be held at 10.30am this morning, 23 March 2021. Analysts who require dial-in details, please contact Buchanan at . A recorded webcast of the analyst conference call, including the investor presentation slides, will be made available this afternoon at this link: hxxps:// The recorded webcast will also be made available at the investor section of Alliance's website, hxxps://
2vdm: RNSthis a.m.: Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the 12 months ended 31 December 2020 on Tuesday 23 March 2021. A conference call for analysts will be held at 10.30am on 23 March 2021; analysts who require dial-in details, please contact Buchanan at A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 23 March 2021 at this link: hxxps:// The recorded webcast will also be made available at the investor section of Alliance's website, hxxps:// For more information, please contact Buchanan on 020 7466 5000 or email
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days ago and part of our discussion includes APH and some others with a similar business model. We also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 39) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Happy New Lockdown !! WD @wheeliedealer hTTps://
winnings1: Has anyone here had a look at Beximco Pharmaceuticals (BXP) This company has been appointed to be the sole distributor of the Oxford vaccine for the whole of Bangladesh. The share price has risen significantly off late, but more to come IMHO. Cheers. But as always do your own research. ws
wba1: Interesting acquisition. I have held this share for a few years, having bought in the low 40s. I originally bought as the business model bears some resemblance (although more OTC focused) to Galen, a company which made me very good profits in the early 2000s. And the more I see of APH the more it behaves like Galen - low risk, throws off free cash flow reliably and makes few mistakes in its dealings. I suspect this deal will be the last until 2022 and I may look to slice some profit if it tops 100p.
2vdm: Also reduced my holdings substantially. I've done very well out of APH and still hold, but I can't see it going anywhere at the moment, although I may re-visit when we have more news
amunro: Tesla is an interesting one. Are they are a car maker or innovator of next gen technology like self driving cars and batteries? As an investor sometimes you just need to follow the market, make money, with the view to getting out when things dive. Its all about managing risk. I got out of APH as I want the money to grow faster than APH offers.
winnings1: I consider APH a sound and quite safe stock in the turbulent markets - of which we have seen some signs yesterday, and almost certainly more turbulance to come, IMHO. In fact, also in the unit trusts terratory, I am mainly invested in the health sector (e.g. Schroder Global Healthcare unit trust). I would, for example, not touch a madly overvalued stock like Tesla, where there is a chance of an implosion some day. We are living in weird times, some shere prices rising out of the pan, yet no certainty anywhere. Take care, keep healthy. Cheeers, WS
winnings1: If an up-to-date purchase (i.e. today) the price would be up, a sale then down, But it could be a correction entry from a deal a few days ago, in which case it explains the then fall in the share price.
winnings1: Share price currently just around 70p, that is cheap in my view. Chairman and his wife bought in June at 77.7p, and at that price the shares were inexpensive, they now look distinctly cheap. I topped up and may yet do some more. Medicines will not go out of fashion.
Alliance Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Alliance P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 15:18:35